Literature DB >> 10064602

Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells.

I Matsumura1, T Kitamura, H Wakao, H Tanaka, K Hashimoto, C Albanese, J Downward, R G Pestell, Y Kanakura.   

Abstract

STAT5 is a member of a family of transcription factors that participate in the signal transduction pathways of many hormones and cytokines. Although STAT5 is suggested to play a crucial role in the biological effects of cytokines, its downstream target(s) associated with cell growth control is largely unknown. In a human interleukin-3 (IL-3)-dependent cell line F-36P-mpl, the induced expression of dominant-negative (dn)-STAT5 and of dn-ras led to inhibition of IL-3-dependent cell growth, accompanying the reduced expression of cyclin D1 mRNA. Also, both constitutively active forms of STAT5A (1*6-STAT5A) and ras (H-rasG12V) enabled F-36P-mpl cells to proliferate without added growth factors. In NIH 3T3 cells, 1*6-STAT5A and H-rasG12V individually and cooperatively transactivated the cyclin D1 promoter in luciferase assays. Both dn-STAT5 and dn-ras suppressed IL-3-induced cyclin D1 promoter activities in F-36P-mpl cells. Using a series of mutant cyclin D1 promoters, 1*6-STAT5A was found to transactivate the cyclin D1 promoter through the potential STAT-binding sequence at -481 bp. In electrophoretic mobility shift assays, STAT5 bound to the element in response to IL-3. Furthermore, the inhibitory effect of dn-STAT5 on IL-3-dependent growth was restored by expression of cyclin D1. Thus STAT5, in addition to ras signaling, appears to mediate transcriptional regulation of cyclin D1, thereby contributing to cytokine-dependent growth of hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064602      PMCID: PMC1171226          DOI: 10.1093/emboj/18.5.1367

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  69 in total

1.  Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.

Authors:  G Watanabe; C Albanese; R J Lee; A Reutens; G Vairo; B Henglein; R G Pestell
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

2.  Stat3 activation is required for cellular transformation by v-src.

Authors:  J F Bromberg; C M Horvath; D Besser; W W Lathem; J E Darnell
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

3.  Stat3 activation by Src induces specific gene regulation and is required for cell transformation.

Authors:  J Turkson; T Bowman; R Garcia; E Caldenhoven; R P De Groot; R Jove
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  Jak2 is essential for signaling through a variety of cytokine receptors.

Authors:  E Parganas; D Wang; D Stravopodis; D J Topham; J C Marine; S Teglund; E F Vanin; S Bodner; O R Colamonici; J M van Deursen; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

5.  Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.

Authors:  H Neubauer; A Cumano; M Müller; H Wu; U Huffstadt; K Pfeffer
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

6.  An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction.

Authors:  H Nakajima; X W Liu; A Wynshaw-Boris; L A Rosenthal; K Imada; D S Finbloom; L Hennighausen; W J Leonard
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

Review 7.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

8.  Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.

Authors:  S Teglund; C McKay; E Schuetz; J M van Deursen; D Stravopodis; D Wang; M Brown; S Bodner; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

9.  Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line.

Authors:  I Matsumura; K Nakajima; H Wakao; S Hattori; K Hashimoto; H Sugahara; T Kato; H Miyazaki; T Hirano; Y Kanakura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation.

Authors:  M Onishi; T Nosaka; K Misawa; A L Mui; D Gorman; M McMahon; A Miyajima; T Kitamura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

View more
  89 in total

1.  Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors.

Authors:  H Chen; J M Lee; Y Zong; M Borowitz; M H Ng; R F Ambinder; S D Hayward
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota.

Authors:  J Mwanjewe; M Spitaler; M Ebner; M Windegger; M Geiger; S Kampfer; J Hofmann; F Uberall; H H Grunicke
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

3.  IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf.

Authors:  Chris Albanese; Kongming Wu; Mark D'Amico; Christy Jarrett; David Joyce; Julian Hughes; James Hulit; Toshiyuki Sakamaki; Maofu Fu; Avri Ben-Ze'ev; Jacqueline F Bromberg; Carmela Lamberti; Udit Verma; Richard B Gaynor; Stephen W Byers; Richard G Pestell
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

4.  Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover.

Authors:  S Lin; W Wang; G M Wilson; X Yang; G Brewer; N J Holbrook; M Gorospe
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

5.  Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.

Authors:  Yongzhi Cui; Greg Riedlinger; Keiko Miyoshi; Wei Tang; Cuiling Li; Chu-Xia Deng; Gertraud W Robinson; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

6.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Carlota Lopez-Cara; Riccardo Rondanin; Daniele Simoni; Ernest Hamel; Stefania Grimaudo; Rosaria Maria Pipitone; Maria Meli; Manlio Tolomeo
Journal:  Eur J Med Chem       Date:  2015-11-27       Impact factor: 6.514

Review 7.  JAK/STAT pathway dysregulation in tumors: a Drosophila perspective.

Authors:  Marc Amoyel; Abigail M Anderson; Erika A Bach
Journal:  Semin Cell Dev Biol       Date:  2014-03-28       Impact factor: 7.727

8.  Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.

Authors:  Terence M Williams; Federica Sotgia; Hyangkyu Lee; Ghada Hassan; Dolores Di Vizio; Gloria Bonuccelli; Franco Capozza; Isabelle Mercier; Hallgeir Rui; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

9.  CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.

Authors:  Gang Yang; Yicheng Wang; Jianchun Xiao; Fangyu Zhao; Jiangdong Qiu; Yueze Liu; Guangyu Chen; Zhe Cao; Lei You; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  Cell Oncol (Dordr)       Date:  2020-10-30       Impact factor: 6.730

10.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.